Abstract
Purpose To evaluate the safety and efficacy of the timolol/dorzolamide fixed combination vslatanoprost 0.005% in exfoliation glaucoma patients.
Methods We randomized in an observer-masked fashion 65 newly diagnosed exfoliation glaucoma patients to either the timolol/dorzolamide twice daily or latanoprost daily treatment for 2 months and then crossed these over to the other treatment.
Results A total of fifty-four patients completed the study. After 2 months of chronic dosing, the morning intraocular pressure (IOP) (10:00) was reduced from a baseline of 31.2±6.5 mmHg to 18.1±3.0 with the fixed combination and to 18.9±4.1 mmHg with latanoprost (P=0.21). Six patients were discontinued early from both treatment periods owing to inadequate IOP control and two others were discontinued from latanoprost treatment only. The fixed combination showed a significantly greater incidence of taste perversion (P<0.001) and stinging upon instillation (P=0.036), while latanoprost showed a trend for increased conjunctival injection (P=0.056). However, five patients demonstrated either bradycardia or asthmatic symptoms with initiation of the fixed combination therapy. One patient on latanoprost complained of dizziness. Patient preference was generally given to latanoprost (63 vs20.3%) mainly because of its once daily dosing (P<0001).
Conclusions This study suggests that both latanoprost and the timolol/dorzolamide fixed combination are efficacious in the treatment of newly diagnosed exfoliation glaucoma.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ritch R, Schlötzer-Schrehardt U . Exfoliation syndrome. Surv Ophthalmol 2001; 45: 265–315.
Vesti E, Kivela T . Exfoliation syndrome and exfoliation glaucoma. Prog Retin Eye Res 2000; 19: 345–368.
Fechtner R, Clineschmidt C, Getson A, Adamsons I . A three month, parallel, randomized, observer-masked, multicenter study comparing Cosopt™ to Xalatan™ in patients with elevated IOP. Invest Ophthalmol Vis Sci 1999; 40: S665.
Konstas AGP, Papapanos P, Tersis I, Houliara D, Holmes KT, Stewart WC . A comparison of the efficacy and safety of latanoprost 0.005% every evening versus timolol/dorzolamide fixed combination twice daily. Invest Ophthalmol Vis Sci 2001; 42: S420.
Konstas AGP, Maltezos AC, Gandi S, Hudgins AC, Stewart WC . Comparison of the 24 hour intraocular pressure reduction with two dosing regimes of latanoprost and timolol in patients with open-angle glaucoma. Am J Ophthalmol 1999; 128: 15–20.
Konstas AGP, Mantziris DA, Stewart WC . Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997; 115: 182–185.
Vogel R . The impact of entry criteria on the baseline IOP in glaucoma studies: a meta-analysis. Invest Ophthalmol Vis Sci 1996; 37: S1099.
Konstas AGP, Jay JL, Marshall GE, Lee WR . Prevalence, diagnostic features, and response to trabeculectomy in exfoliation glaucoma. Ophthalmology 1993; 100: 619–627.
Book SA . Essentials of Statistics. McGraw-Hill: New York, 1978.
Siegel S . Non Parametric Statistics. Series in Psychology. McGraw-Hill: New York, 1956.
Stjernschantz JW . From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci 2001; 42: 1134–1145.
Nilsson SFE, Samuelsson M, Bill A, Stjernschantz J . Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2a-1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989; 48: 707–716.
Gabelt BT, Kaufman PL . Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989; 49: 389–402.
Kerstetter JR, Brubaker RF, Wilson SE, Kullerstrand LJ . Prostaglandin F2a-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am J Ophthalmol 1988; 105: 30–34.
Toris CB, Camras CD, Yablonski ME . Effects of PhXA41, a new prostaglandin F2a analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993; 100: 1297–1304.
Alm A, Stjernschantz J, Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995; 102: 1743–1752.
Camras CB, United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103: 138–147.
Watson P, Stjernschantz J, Scandinavian Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126–137.
Stewart WC . Current and Future Glaucoma Therapy, Ciba Vision Ophthalmics: Duluth, GA, 1997, pp 1–43.
Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC . Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999; 77: 668–672.
Moroi SE, Gottfredsdottir MS, Schteingart MT, Elner SG, Lee CM, Schertzer RM et al.. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999; 106: 1024–1029.
Kaufman HE, Varnell ED, Thompson HW . Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol 1999; 127: 531–536.
Stewart WC . New perspectives in the medical treatment of glaucoma. Curr Opin Ophthalmol 1999; 127: 142–147.
Boyle JE, Ghosh K, Gieser DK, Adamsons IA, Dorzolamide–Timolol Study Group. A randomized trial comparing the dorzolamide–timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 1998; 105: 145–151.
Clineshmidt CM, Williams RD, Snyder E, Adamsons IA . A randomized trial in patients inadequately controlled on timolol alone comparing the dorzolamide–timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 1999; 106: 17–24.
Boyle JE, Ghosh K, Gieser DK, Adamsons IA . A randomized trial comparing the dorzolamide–timolol combination given twice daily to monotherapy with timolol or dorzolamide. Ophthalmology 1999; 106: 10–16.
Hutzelmann J, Owens S, Sedden A, Adamsons I, Vargas E . Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol 1998; 82: 1249–1253.
Stewart WC, Garrison PM . β-blocker-induced complications and the glaucoma patient: newer treatments to help reduce systemic side effects. Arch Int Med 1998; 158: 221–226.
Heijl A, Strahlman E, Sverrisson T et al. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology 1997; 104: 137–142.
Konstas AGP, Maltezos T, Bufidis T, Hudgins AC, Stewart WC . 24 hour control of IOP with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Eye 2000; 14: 73–77.
Konstas AGP, Lake S, Maltezos AC, Holmes KT, Stewart WC . 24 hour intraocular pressure reduction with latanoprost compared to pilocarpine as third line therapy in exfoliation glaucoma. Eye 2001; 15: 59–62.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was not supported by an outside granting company or agency
Rights and permissions
About this article
Cite this article
Konstas, A., Kozobolis, V., Tersis, I. et al. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye 17, 41–46 (2003). https://doi.org/10.1038/sj.eye.6700257
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6700257
Keywords
This article is cited by
-
Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future
Advances in Therapy (2021)
-
Genetics, Diagnosis, and Monitoring of Pseudoexfoliation Glaucoma
Current Ophthalmology Reports (2016)
-
Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs
Japanese Journal of Ophthalmology (2012)
-
Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components
Eye (2008)
